Press Releases

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired JB Laboratories for approximately $44 million in cash. Based in Holland, Michigan, privately-held JB Laboratories is...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Judy Brown, Perrigo's CFO will present at the Merrill Lynch Global Pharmaceutical Conference on Tuesday, September 16 at the Merrill...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired the exclusive U.S. rights to sell and distribute Levocetirizine tablets, the generic version of UCB's Xyzal®...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fourth quarter and full year ended June 28, 2008. Perrigo's Chairman and CEO Joseph C. Papa commented, "For the third...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on September 16, 2008 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it began shipping Famotidine Complete chewable tablets (famotidine 10 mg; calcium carbonate 800mg; magnesium hydroxide 165 mg) to...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Judy Brown, Perrigo's Chief Financial Officer, will present at the Bank of America Specialty Pharmaceuticals Conference on Thursday,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Bank of America Specialty Pharmaceuticals Conference on Thursday,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2008 on Monday, August 18, 2008 at approximately 8:00 a.m. (ET). The Company...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO), the world's largest manufacturer of over-the-counter healthcare products sold under the store-brand label, announced today its intent to invest $10.5...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors has appointed Ellen R. Hoffing as a new director of the Company. Joseph C. Papa, Perrigo's Chairman,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Syrup...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application (ANDA) for Fluocinonide Cream 0.1%, a generic version of VANOS® Cream 0.1%. The...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has entered into a collaborative agreement with Cobrek Pharmaceuticals, a newly formed entity of Pentech Pharmaceuticals Inc., a...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Citi Investment Research Global Health Care Conference on Wednesday,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its third quarter fiscal year 2008 and nine months ended March 29, 2008. Perrigo Company (in thousands, except per share...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on June 20, 2008 to shareholders of record on May...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter (OTC) Nicotine Polacrilex...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its third quarter fiscal 2008 on Tuesday, May 6, 2008 at approximately 8:00 a.m. (ET). The...

ALLEGAN, Mich., April 21 /PRNewswire-FirstCall/ .- Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application (ANDA) for over-the-counter...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC)...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 12th Annual Sidoti Emerging Growth Institutional Investor Forum on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that the United States District Court for the District of New Jersey has denied Connetics Corporation's motion for a preliminary...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), has received final approval from the U.S. Food and Drug...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has begun shipping 20 mg Omeprazole delayed released tablets to its retail customers. This product delivers the same medicine at...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's Chairman and CEO will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device...

-- Second quarter revenue increased $65 million, or 17 percent, to $435 million -- GAAP net income increased 63 percent to $34 million, or $0.36 per share -- Second quarter cash provided by...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that the Board of Directors has authorized the repurchase of $150 million of the Company's common stock through February 1, 2010...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal 2008 on Tuesday, February 5, 2008 at approximately 8:00 a.m. (ET)....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has acquired Galpharm Healthcare, Ltd. for $86 million in cash. Based in Barnsley, Yorkshire, United Kingdom, privately-held...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 26th Annual JPMorgan Healthcare Conference on Wednesday, January 9, at...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to Dexcel Pharma Technologies, Ltd. for 20 mg Omeprazole...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2008 first quarter that ended September 29, 2007. Perrigo Company (in thousands, except per share...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Dexcel Pharma Technologies, Ltd. ("Dexcel"), Perrigo's partner for store brand OTC 20mg Omeprazole delayed release tablet, has...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors appointed President and Chief Executive Officer, Joseph C. Papa, to be Chairman of its Board of Directors....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on December 18, 2007 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2008 on Thursday, November 1, 2007 at approximately 8:00 a.m. (ET)....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it had filed an Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg, a generic version of...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Ciclopirox Topical Solution,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that President and CEO, Joseph C. Papa and the Perrigo management team will provide a review of the Company business for the financial...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Mori Arkin, Vice Chairman and General Manager, Perrigo Global Generics and API, has advised the Company that he will retire at the...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for fiscal year 2007 and the fourth quarter ended June 30, 2007. Perrigo Company (in thousands, except per share amounts) Fourth...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.045 per share, payable on September 18, 2007 to shareholders of...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2007 on Thursday, August 23, 2007 at approximately 8:00 a.m. (ET). The Company...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has closed its transaction to acquire Qualis, Inc., a privately-owned manufacturer of store brand pediculicide products for...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the U.S. Food & Drug Administration (FDA) has granted tentative approval to Dexcel Pharma Technologies, Ltd. (Dexcel) for its...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph C. Papa, Perrigo's President and CEO will present at the Goldman Sachs Twenty-Eighth Annual Global Healthcare Conference on...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that a federal court has ruled in its favor in patent litigation involving Famotidine Complete. Perrigo had been sued by Johnson &...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter coated nicotine polacrilex...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for the third quarter of fiscal year 2007 ended March 31, 2007. Perrigo Company (in thousands, except per share amounts)...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.045 per share, payable on June 19, 2007 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's President and CEO will present at the Morgan Stanley Global Healthcare Unplugged Conference on Thursday, May...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its third quarter fiscal 2007 on Tuesday, May 8, 2007 at approximately 8:00 a.m. (ET). The...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's President and CEO will present at the CIBC World Markets Biotechnology & Pharmaceuticals Conference on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced an organizational restructuring to further enhance the management of the Company's global operations. John Hendrickson has been named...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has entered into a purchase agreement to acquire Qualis, Inc., a privately-owned manufacturer of store brand pediculicide...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's President and CEO will present at the Citigroup Small & Mid-Cap Conference on Tuesday, March 13, at 10:45...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced the appointment by the Board of Directors of Ben-Zion Zilberfarb as a new director of the Company. Dr. Zilberfarb was appointed to...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that the Board of Directors has authorized the repurchase of $60 million of the Company's common stock through February 8, 2009 under...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's President and CEO will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for the second quarter of fiscal year 2007 ended December 30, 2006. Perrigo Company (in thousands, except per share amounts)...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal 2007 on Thursday, Feb. 1, 2007 at approximately 7:30 a.m. (ET). The...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's President and CEO will present at the 25th Annual JPMorgan Healthcare Conference on Thursday, January 11,...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market Simvastatin Tablets, USP, 5 mg, 10 mg, 20...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Ciclopirox Topical...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the U. S. Food & Drug Administration (FDA) has issued an approvable letter for Dexcel Pharma Technologies, Ltd.'s New Drug...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.045 per share, payable on December 19, 2006 to shareholders of record...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) has released the following information regarding its voluntary recall announced early this morning. The voluntary recall was tied to certain lots of...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has initiated a voluntary, nationwide product recall to the retail level of certain lots of its store brand Acetaminophen 500...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2007 first quarter that ended September 30, 2006. Perrigo Company (in thousands, except per share...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2007 on Tuesday, Oct. 31, 2006 at approximately 8:30 a.m. (ET). The...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today welcomed Joe Papa as its President and Chief Executive Officer. Mr. Papa succeeds Dave Gibbons who is now the Company's Executive Chairman of...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) will conduct a brief conference call at 10:00 a.m. (ET) on October 10, 2006 introducing Joe Papa as President and Chief Executive Officer. There will be...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has been granted tentative approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market over-the- counter (OTC)...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors has elected Joseph C. Papa as its President and Chief Executive Officer effective October 9. Mr. Papa...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Perrigo Israel Pharmaceuticals subsidiary has been granted tentative approval from the U. S. Food and Drug Administration...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0425 per share, payable on September 19, 2006 to shareholders of...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for the full year and fourth quarter ended July 1, 2006. Perrigo Company (in thousands, except per share amounts) Fourth...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner, InvaGen Pharmaceuticals, Inc., has received tentative approval from the U.S. Food and Drug Administration (FDA) on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2006 on Wednesday, Aug. 9, 2006 at approximately 8:30 a.m. (ET). The Company...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Judy L. Brown has assumed the role of Executive Vice President, Chief Financial Officer and Chief Accounting Officer effective...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner, Kali Laboratories, Inc., a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), has received...

Since the acquisition of Agis, Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) has pursued opportunities to integrate both businesses and to make them as efficient as possible, while at the same time...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has received approval from the U. S. Food and Drug Administration (FDA) to market over-the-counter (OTC) coated nicotine...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announces its association with Dexcel Pharma Technologies, Ltd.'s new drug application for a generic version of Prilosec OTC®. Under the terms of an...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0425 per share, payable on June 20, 2006 to shareholders of record on...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) invites the public to access a webcast of Chairman, President and CEO, David Gibbons' presentation at the Bank of America 2006 Health Care Conference...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today acknowledges its association with the patent challenge of NASACORT® AQ initiated by Barr Laboratories, Inc. a subsidiary of Barr Pharmaceuticals,...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for the third quarter of fiscal year 2006 ended March 25, 2006. The acquisition of Agis Industries was completed on March 17,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its third quarter fiscal 2006 on Thursday, April 27, 2006 at approximately 8:30 a.m. (ET). The...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that its shareholder Rights Agreement expired on April 10, 2006. The Company said there were no plans to renew it. The Perrigo...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market terconazole vaginal...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) invites the public to access a webcast of Chairman, President and CEO, Dave Gibbons' presentation at the Bank of America 2006 Consumer Conference on...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Ciclopirox Olamine Cream USP,...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Chief Financial Officer Douglas R. Schrank will retire from his post on June 30, 2006. Judy L. Brown, Senior Vice President and...